GSK3B, glycogen synthase kinase 3 beta, 2932

N. diseases: 393; N. variants: 25
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032580
Disease: Adenomatous Polyposis Coli
Adenomatous Polyposis Coli 		0.100 Biomarker disease BEFREE This suggests a possible link between Axin, the Wnt-1 signaling components beta-catenin and glycogen synthase kinase 3 beta (GSK3 beta), and APC. 9601641 1998
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 Biomarker disease BEFREE The PSEN1 binding protein glycogen synthase kinase-3 beta (GSK-3 beta) has been considered as a key protein in AD pathogenesis since GSK-3 beta phosphorylates tau and hyperphosphorylated tau is a main component of neurofibrillary tangles associated to AD. 10754226 2000
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 PosttranslationalModification disease BEFREE Glycogen synthase kinase 3 beta (GSK3 beta) phosphorylates the microtubule associated protein tau at sites that are aberrantly phosphorylated in AD. 11326302 2001
CUI: C0494463
Disease: Alzheimer Disease, Late Onset
Alzheimer Disease, Late Onset 		0.320 Biomarker disease BEFREE Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. 11326302 2001
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 GeneticVariation disease BEFREE Main genes involved in AD include mutational loci (APP, PS1, PS2, TAU) and multiple susceptibility loci (APOE, A2M, AACT, LRP1, IL1A, TNF, ACE, BACE, BCHE, CST3, MTHFR, GSK3B, NOS) distributed across the human genome. 12369958 2002
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 Biomarker disease LHGDN GSK3beta signalling: casting a wide net in Alzheimer's disease. 12566926 2003
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 GeneticVariation disease BEFREE Sarkosyl-insoluble fractions of the hippocampus were enriched in p38-P and GSK-3 beta-P in Alzheimer's disease (AD) cases, processed in parallel for comparative purposes, but not in the P310L mutation. 14757934 2003
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.600 Biomarker disease RGD Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia. 12644246 2003
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.600 Biomarker disease LHGDN The possible role of GSK-3 beta, a pro-apoptotic factor participating in signal transduction involved in cell survival, is discussed in relation to schizophrenia. 14518171 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.340 Biomarker group LHGDN Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. 14617795 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.340 PosttranslationalModification group LHGDN Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. 12900420 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.100 AlteredExpression disease LHGDN GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. 12969793 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.100 AlteredExpression disease LHGDN Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. 12603528 2003
CUI: C1292753
Disease: Primary Effusion Lymphoma
Primary Effusion Lymphoma 		0.010 AlteredExpression disease LHGDN The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. 12829841 2003
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.600 GeneticVariation disease BEFREE No association was detected between GSK3-beta -50 T/C SNP and the presence of bipolar illness. 14729229 2004
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.600 GeneticVariation disease BEFREE Homozygotes for the mutant allele of GSK3-beta promoter (-50T/C) SNP showed a later onset of bipolar illness, and better acute effects of TSD treatment on perceived mood (as rated on VAS). 15351432 2004
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.600 Biomarker disease LHGDN GSK-3beta in cerebrospinal fluid of schizophrenia patients. 15254796 2004
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.600 Biomarker disease CTD_human Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. 14745448 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.400 Biomarker disease BEFREE We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3 beta affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3beta and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. 14985354 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.100 Biomarker disease BEFREE We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3 beta affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3beta and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. 14985354 2004
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.090 Biomarker group LHGDN These results suggest that GSK3beta is a critical intermediate in pro-apoptotic signaling cascades that are associated with neurodegenerative diseases, thus providing a potential target site amenable to pharmacological intervention. 15132987 2004
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.090 Biomarker group BEFREE These results suggest that GSK3beta is a critical intermediate in pro-apoptotic signaling cascades that are associated with neurodegenerative diseases, thus providing a potential target site amenable to pharmacological intervention. 15132987 2004
CUI: C1739135
Disease: Progression of prostate cancer
Progression of prostate cancer 		0.010 AlteredExpression disease BEFREE Because glycogen synthase kinase-3 beta activity is suppressed after the enzyme is phosphorylated by protein kinase B/Akt and Akt activity frequently increases during the progression of prostate cancer, nullification of the glycogen synthase kinase-3 beta-mediated suppression of androgen receptor activity by Akt likely contributes to prostate cancer progression. 14985354 2004
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.700 AlteredExpression disease LHGDN Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. 15555766 2005
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.600 GeneticVariation disease BEFREE A single nucleotide polymorphism (SNP) (-50 T/C) falling into the effective promoter region (nt -171 to +29) of the gene coding for glycogen synthase kinase 3-beta (GSK3-beta) has been linked with different age at onset of bipolar illness and with different antidepressant effects of total sleep deprivation. 15694273 2005